Background Lung cancer is the leading cause of cancer-related deaths worldwide (Ferlay et
al., Int J Cancer 136: E359–386, 2015). In addition, lung cancer is associated with the …

Immunotherapy has emerged as an effective treatment for various types of cancers. Recent
studies have highlighted a significant correlation between the gut microbiome and patients' …

Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for
hematologic malignancies, however, response rates and associated immune-related …

Several studies in recent times have linked gut microbiome (GM) diversity to the
pathogenesis of cancer and its role in disease progression through immune response …

The gut microbiota (GM) is considered to constitute a powerful “organ” capable of
influencing the majority of the metabolic, nutritional, physiological, and immunological …

Immunotherapy using immune checkpoints inhibitors has become the standard treatment for
first and second line therapy in patients with non-small cell lung cancer (NSCLC). However …

Lung cancer is the leading cause of cancer deaths worldwide, mainly because it is usually in
the advanced stage at the time of diagnosis. Although great progress has been made in the …

Lung cancer is one of the deadliest and most common malignancies in the world,
representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly …

The gut microbiota influences anti-tumor immunity and can induce or inhibit response to
immune checkpoint inhibitors (ICIs). Therefore, microbiome features are being studied as …

The microbiome is extremely important for human health; more recently its role in the context
of cancer became clear. Microbial effects range from enhancing cancer immunity and cancer …